The reliability and integrity of overall survival data based on follow-up records only and potential solutions to the challenges-Reference-Cited by-同舟云学术

The reliability and integrity of overall survival data based on follow-up records only and potential solutions to the challenges

Published:2023-02 Issue: Volume:31 Page:100624
ISSN:2666-6065
Container-title:The Lancet Regional Health - Western Pacific
language:en
Short-container-title:The Lancet Regional Health - Western Pacific

Author:

Huang Huiyao,Tang Yu,Yu Yue,Yu Anqi,Wu Dawei,Fang Hong,Wang Shuhang,Sun Chao,Wang Xin,Fan Qi,Fang Yuan,Tang Qiyu,Jiang Ning,Du Jingting,Miao Huilei,Bai Ying,Ma Peiwen,Xing Shujun,Cui Dandan,Miao Shuangman,Jiang Yale,Zhu Jingxiao,Zhu Qi,Leng Ye,Guo Lan Wei,Liao Shanmei,Shao Yaguang,Song Yinyin,Liu Zeyuan,Hong Minghuang,Luo Suxia,Xu Binghe,Lan Gongtao,Li Ning

Publisher

Elsevier BV

Subject

Infectious Diseases,Psychiatry and Mental health,Geriatrics and Gerontology,Public Health, Environmental and Occupational Health,Obstetrics and Gynecology,Health Policy,Pediatrics, Perinatology and Child Health,Internal Medicine

Reference41 articles.

1. FDA acceptance of surrogate end points for cancer drug approval: 1992-2019;Chen;JAMA Intern Med,2020

2. Evaluation of the clinical benefit of cancer drugs submitted for reimbursement recommendation decisions in Canada;Meyers;JAMA Intern Med,2021

3. Evaluation of overall response rate and progression-free survival as potential surrogate endpoints for overall survival in immunotherapy trials;Mushti;Clin Cancer Res,2018

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022;eClinicalMedicine;2023-09